Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT01023217
- Locations
- 🇰🇷
Asan Medical Center, Seoul, the Meteropolis of Seoul, Korea, Republic of
Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT01013272
- Locations
- 🇨🇳
The University of Hong Kong, Hong Kong, China
Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 27
- Registration Number
- NCT01005238
- Locations
- 🇨🇭
University Hospital, Basel, Switzerland
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
Phase 3
Completed
- Conditions
- MalariaHIV Infections
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 389
- Registration Number
- NCT00993031
- Locations
- 🇺🇬
Tororo District Hospital, Tororo, Uganda
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Phase 4
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00986778
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
Phase 2
Completed
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 12
- Registration Number
- NCT00915655
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 462
- Registration Number
- NCT00823550
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection
Phase 4
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT00810524
- Locations
- 🇨🇳
The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
Phase 2
Completed
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
Phase 4
Terminated
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2011-06-23
- Lead Sponsor
- Inje University
- Target Recruit Count
- 30
- Registration Number
- NCT00798460
- Locations
- 🇰🇷
Ilsanpaik hospital, Goyang, Gyunggi, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath